Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of nonalcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases with significant unmet medical need, announces today that its management team will participate in two investor conferences during the months of January and February 2022.